Maze Therapeutics, Inc. (MAZE)
(Delayed Data from NSDQ)
$14.51 USD
-0.74 (-4.85%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $14.51 0.00 (0.00%) 5:02 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MAZE 14.51 -0.74(-4.85%)
Will MAZE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MAZE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for MAZE
12 Health Care Stocks Moving In Monday's After-Market Session
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Maze Therapeutics (MAZE) Receives Buy Rating from HC Wainwright & Co. | MAZE Stock News
Maze Therapeutics (MAZE) Receives Positive Rating and Outlook | MAZE Stock News
Maze Therapeutics initiated with bullish view at H.C. Wainwright, here's why